Company / Financials
Revolution Medicines, Inc. Financials
FY2018-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableRevenue
$0
FY2025
Net Income
-$1.1B
FY2025 · -88.5% YoY
Profit Margin
-
FY2025 · net income / revenue
ROE
-69.3%
FY2025 · return on equity
Total Assets
$2.4B
FY2025
Total Debt
-
FY2025
Equity
$1.6B
FY2025
ROA
-48.0%
FY2025 · return on assets
Statement paths
Financial highlights
Key Data Points
- Low Piotroski F-Score: 1/9 (multiple financial health concerns)
- Altman Z-Score -1.10 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Metric history
Revenue HistoryTotal revenue from operations$0Net Income HistoryProfit after all expenses and taxes-$1.1B-88.5% YoYOperating Income HistoryProfit from core business operations before interest and taxes-$1.2B-71.5% YoYSG&A Expense HistorySelling, general, and administrative expenses$195.0M+100.5% YoYR&D Expense HistoryResearch and development spending$987.3M+66.7% YoYInterest Expense HistoryCost of borrowing and debt obligations$71.0KIncome Tax HistoryTotal income tax expense$0+100.0% YoYEPS (Basic) HistoryBasic earnings per share-$3.86-25.3% YoYEPS (Diluted) HistoryDiluted earnings per share including stock options and convertibles-$3.86-25.3% YoYShares Outstanding HistoryWeighted average diluted shares outstanding185.9M+12.9% YoY